` 326030 (SK Biopharmaceuticals Co Ltd) vs KOSPI 200 Comparison - Alpha Spread

326030
vs
KOSPI 200

Over the past 12 months, has significantly outperformed KOSPI 200, delivering a return of 20% compared to the KOSPI 200's 8% drop.

Stocks Performance
326030 vs KOSPI 200

Loading
326030
KOSPI 200
Add Stock

Performance Gap
326030 vs KOSPI 200

Loading
326030
KOSPI 200
Difference

Performance By Year
326030 vs KOSPI 200

Loading
326030
KOSPI 200
Add Stock

Competitors Performance
SK Biopharmaceuticals Co Ltd vs Peers

KOSPI 200
326030
LLY
JNJ
NOVO B
ROG
Add Stock

SK Biopharmaceuticals Co Ltd
Glance View

Market Cap
8.1T KRW
Industry
Pharmaceuticals

SK Biopharmaceuticals Co., Ltd., a prominent player in the global biopharmaceutical industry, emerged as a distinctive entity out of one of South Korea's largest conglomerates, the SK Group. This pharmaceutical jewel draws its strength from innovation in the neurology and oncology sectors, fields brimming with both challenge and opportunity. At its core, SK Biopharmaceuticals is dedicated to the research, development, and commercialization of novel medications, with a significant focus on disorders impacting the central nervous system. Their pipeline and commercial activities revolve around cutting-edge therapies, such as the epilepsy drug Cenobamate, which has gained a foothold in both the U.S. and European markets. This drug, marketed under different names like Xcopri in the U.S., is a testament to the company's ability to leverage robust R&D capabilities into profitable products. Revenue generation for SK Biopharmaceuticals is predominantly driven by the sales of their innovative therapeutic solutions, as well as strategic collaborations with a network of global partners. They engage in a lifecycle approach where they not only develop and launch their own drugs but also license out their intellectual property, enhancing revenue streams through royalties and milestone payments. This hybrid model of sales and strategic partnerships showcases a deft mix of scientific prowess and commercial acumen, key to sustaining and propelling growth in a competitive market. Additionally, they continuously invest in research and alliances, aiming to expand their portfolio beyond existing successes, while targeting unmet medical needs that mirror their core strengths. This balanced approach positions SK Biopharmaceuticals not just as a standalone drugmaker, but as a dynamic player in shaping future therapies in their chosen niches.

Intrinsic Value
47 234.25 KRW
Overvaluation 54%
Intrinsic Value
Price
Back to Top